ArticleKidney international reports2025
The Double-Icodextrin Dose Randomized Controlled Trial of a Double Icodextrin Dose for Older Patients on Incremental Continuous Ambulatory Peritoneal Dialysis.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Clinical efficacy and safety of icodextrin dialysate for overnight dwell in continuous ambulatory peritoneal dialysis: A prospective self-controlled study.The Journal of international medical research · 2026Observational
- Clinical rationale behind glucose-sparing strategies in peritoneal dialysis: a narrative review.BMC nephrology · 2026Review
- Response to the Letter to the Editor Entitled "A Critical Appraisal of End Points and Statistical Strategies in the DIDo Trial".Kidney international reports · 2025Article
- A Critical Appraisal of End Points and Statistical Strategies in the DIDo Trial.Kidney international reports · 2025Article
- Use of 2 Icodextrin Exchanges per Day in Incident Peritoneal Dialysis Patients: Are There Incremental Benefits?Kidney international reports · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Icodextrin enhances ultrafiltration (UF) in patients on peritoneal dialysis (PD) but is restricted to 1 bag/d, according to regulatory authorities. The Double-Icodextrin Dose (DIDo) study is a prospective randomized trial investigating the superiority and safety of using 2 bags/d versus 1 bag/d of icodextrin to extend incremental (3 bags/d) continuous ambulatory PD (CAPD) duration in older incident patients. Methods: After a 2-month "run-in" period, the patients were randomized to 2 icodextrin ("double dose") + 1 glucose or 1 icodextrin ("single dose") + 2 glucose dialysates daily. The primary end point was a composite of excessive use of hypertonic dialysates, transfer to another dialysis modality (automated PD [APD], nonincremental CAPD, or hemodialysis) or death at month 9. Secondary end points included mortality, daily UF, technique survival, rates of peritonitis and hospitalizations, and safety at month 18. Results: Forty-one patients were randomized to double dose and 42 to single-dose icodextrin. Baseline characteristics were well-balanced between groups. At month 9, the proportion of patients who discontinued 3 exchanges/d was similar between those receiving the double and the single icodextrin dose (16 [39%] vs. 21 [50%]; HR: 0.69; 95% confidence interval: 0.35-1.33). The results were similar at month 18. Patients in the double dose icodextrin had higher net UF and less hypertonic dialysates use. Rates of peritonitis, hospitalizations, residual urine output decline and serious adverse events (SAEs) were similar between both groups. Conclusion: In older patients on incremental CAPD, the double icodextrin dose did not reduce the primary outcome incidence compared with the single icodextrin dose. Significantly enhanced UF was observed in the double icodextrin dose group and no safety issue was identified.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.